# A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

> **NCT06131372** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 626 (actual)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes
- Obesity

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06131372
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-01
- **Primary completion:** 2025-09-24
- **Final completion:** 2025-11-06
- **Target enrollment:** 626 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06131372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06131372, "A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06131372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*